 |
|
SATURDAYOctober 16SESSION 43:45– 4:00Click here to return to Dermatology Update 2004 Schedule and Abstracts |
David W.C. Hunt PDT utilizes drugs which can be activated by visible wavelengths of light to yield therapeutic effects in a wide range of medical conditions. It has been found that following application of the photosensitizer lemuteporfin (QLT0074) in a topical ointment (LTO) formulation to shaved Balb/c mouse skin, drug-specific fluorescence was largely restricted to pilosebaceous units (PSU). Photosensitizer uptake by the inter-follicular epidermis and the dermis was far less evident. It was subsequently determined by histological analyses that the number of sebaceous glands detectable in mouse skin was substantially reduced at 3 days post-PDT with treatment conditions which elicited minor and transient skin photosensitivity reactions. The depleting effect of PDT on mouse sebaceous glands was red light dose-dependent and sub-optimal when relatively short drug skin contact times were evaluated. These preclinical animal studies provide supporting evidence that PDT using LTO might represent a treatment for human sebaceous gland disorders.
Click here to return to Dermatology Update 2004 Schedule and Abstracts |